Compare FCF & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCF | DAWN |
|---|---|---|
| Founded | 1934 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1994 | 2021 |
| Metric | FCF | DAWN |
|---|---|---|
| Price | $18.83 | $21.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $19.75 | ★ $24.43 |
| AVG Volume (30 Days) | 708.9K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 5.76 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $16.32 | $55.03 |
| Revenue Next Year | $6.25 | $28.12 |
| P/E Ratio | $12.80 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $14.31 | $5.64 |
| 52 Week High | $19.14 | $21.50 |
| Indicator | FCF | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 68.11 | 79.82 |
| Support Level | $16.28 | $10.30 |
| Resistance Level | $19.02 | $21.50 |
| Average True Range (ATR) | 0.33 | 0.03 |
| MACD | 0.08 | -0.31 |
| Stochastic Oscillator | 82.30 | 77.78 |
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.